Study of Lipid Profile in Patients of Polycystic Ovarian Syndrome Before and After Metformin Therapy

  • Noora Saeed aligarh muslim university
  • Nishat Afroz JNMCH, AMU
  • Sheelu Shafiq Siddiqi JNMCH, AMU
  • Aaliya Ehsan JNMCH
  • Mohd Rafey JNMCH
Keywords: metformin, polycystic ovary syndrome, lipid profile


BACKGROUND: Polycystic ovary syndrome (PCOS) is the most common metabolic and endocrine disorders affecting 5-10% of women in their reproductive age. The main objective of this study was to evaluate the effect of metformin on serum lipid profile in patients of polycystic ovary syndrome.METHODS: An observational prospective study conducted at Rajiv Gandhi Centre for Diabetes and Endocrinology and Department of Pathology, JN Medical College AMU from December 2012 to November 2015. All PCOS women were randomized into two group; one group were received Metformin therapy for 6 months duration and the other group were kept on placebo and followed for the same period. All studied women were subjected to measurement of overnight fasting lipid profile which included total cholesterol, triglycerides, high density lipoprotein cholesterol and low density lipoprotein cholesterol.RESULTS: For women who received Metformin, there was significant improvement in the biochemical profile with a significant p value of <0.001.CONCLUSION: Metformin have been shown to improve the lipid profiles leading to increase in the high density lipoprotein cholesterol, the main predictive of cardiovascular disease in the women with polycystic ovary syndrome. DOI: 10.21276/APALM.1226

Author Biographies

Noora Saeed, aligarh muslim university
department of pathology, senior resident
Nishat Afroz, JNMCH, AMU
Professor, Department of Pathology, JNMCH, AMU
Sheelu Shafiq Siddiqi, JNMCH, AMU
Associate Professor, Rajiv Gandhi Centre for Diabetes and Endocrinology, JNMCH, AMU
Aaliya Ehsan, JNMCH
Junior resident, Department of Pathology, JNMCH, AMU
Mohd Rafey, JNMCH
Junior resident, Department of Pathology, JNMCH, AMU


1. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352: 1223-36.
2. Al-Inany H, Johnson N. Drugs for anovulatory infertility in polycystic ovary syndrome. BMJ 2006; 332:1461–62.
3.Michelmorek, Balen AH, Dunger DB, Vezelymp.Poycystic ovaries and associated clinical and biochemical features in young women.Clinendocrinol(Oxford).1999;51:779-86.
4. Futterweit W, Mechanick JI. Polycystic ovarian disease: etiology diagnosis, and treatment. ComprTher. 1988;14:12–20.
5. Dahlgren E, Janson PO, Johansson S, et al. Polycystic ovary syndrome and risk for myocardial infarction. ActaObstetGynecolScand 1992;71:599–603.
6. Hopkinson Z, Satter N, Fleming R et al. Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology, BMJ 1998;317:329-32.
7. Kiddy DS, Sharp PS, White DM, et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases.ClinEndocrinol (Oxf) 1990; 32:213-20.
8.Shaw LJ, BaireyMerz CN, Azziz R, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health-National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J ClinEndocrinolMetab 2008, 93:1276-1284.
9. Messaoudi S, Rongen GA, Riksen, "The cardioprotective effects of metformin". Current Opinion in Lipidology 2011;22: 445–53.
10. Dunaif A, Insulin resistance and polycystic ovary syndrome: mechanism and implication for pathogenesis. Endocrine Review 1997; 18: 774-800.
11.Bengtsson C, Bjorkelund C, Lapidusal, Lissnerl. Association of serum lipid concentration and obesity with mortality in women. Twenty years fellow up of participants in prospective population study in Gothenbrg, sweden. Br Med J 1993:1385-88.
12. Zawadski JK, Dunaif A . Diagnostic criteria for polycystic ovary syndrome. Towards a rational approach in: polycystic ovary syndrome. 1992:377-84.
13.Jacobs HS. Polycystic ovaries and polycystic ovary syndrome.GynecolEndocrinol 1987;1:113-31.
14. Fadhil AZ, Al-Dahhan F. The Effect of Metformin on Serum Lipids in Overweight and Obese Patients with Polycystic Ovary Syndrome.The Iraqi Postgraduate Medical Journal. 2014;13:3.
15. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann intern Med 2002;17:2495-99
Original Article

Most read articles by the same author(s)